Keppra (Levetiracetam) Patent Expiration, LOE Window & CMS Spending

Keppra (Levetiracetam) by Ucb: FDA Orange Book LOE 2031-12-07, 22 AB generics, $117.7M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUcb
FDA Application & PathwayN021035 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-12-07
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors22
2024 CMS Total Public Spend$117.7M
2024 Medicare Part D Spend$71.7M
2024 Medicaid Spend$46.0M
Reported Wholesale Price Change (CA SB 17)16 WAC filings (max 18.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.